https://www.selleckchem.com/pr....oducts/geneticin-g41
NOAC treatment cessation rate was 1.4% (95%CI0.3-4%) during the first year of follow-up. All the patients with TE events had a CHA DS -VASc score ≥ 2 and impaired sRV systolic function at baseline. The total incidence of major events during follow-up was significantly lower compared to historical use of VKAs or aspirin before study inclusion (1.4% (95%CI0.29-4%) vs 6,9% (95%CI2.5-15.2%); p = .01). In this prospective study, NOACs appear to be well-tolerated, with excellent efficacy and safety at mid-term in patients with
Curtir
Comentario
Compartilhar
